News & Updates

Dextrose gel to prevent transitional neonatal hypoglycaemia may do more harm than good

Administering a single dose of dextrose gel as prophylaxis against transitional neonatal hypoglycaemia does not help with the risk of neurocognitive impairment at early school age and even appears to have adverse effects on psychological well-being, according to a study.

Patients with MASLD face heightened diabetes risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) carries an increased risk of type 2 diabetes (T2D), with the risk increase disproportionately higher for individuals with earlier-onset MASLD, as shown in a study.

Cagrilintide–semaglutide improves glycaemic control in early-stage diabetes

Treatment with the combination of cagrilintide plus semaglutide is safe and efficacious for lowering glycaemic levels in individuals with early-stage type 2 diabetes inadequately controlled with diet and exercise, as shown in the phase IIIa REIMAGINE 1 trial.

SGLT2 inhibitor use helps reduce cardiovascular, renal deaths

Patients with diabetes mellitus, heart failure, or chronic kidney disease treated with sodium glucose co-transporter-2 inhibitors (SGLT2i) have a reduced risk of mortality from cardiovascular and renal causes, according to a study.

Semaglutide associated with reduced ICH risk in LVO treated with reperfusion therapy

Co-treatment with yoga plus camelina sativa powder improves outcomes in women with T2D

In women with type 2 diabetes (T2D), performing yoga in addition to supplementation with camelina sativa powder (CSP) delivers improvements in glycaemic indices, oxidative stress, and inflammatory markers, according to a study.

Okra supplementation may lower cardiovascular risk in prediabetes, T2D, diabetic nephropathy

Okra supplementation is beneficial to patients with prediabetes, type 2 diabetes (T2D), or diabetic nephropathy, conferring beneficial effects on lipid profile, diastolic BP, and inflammation markers, according to a systematic review and meta-analysis.

Original New Drug Application Approvals by US FDA (16-30 June 2026)

New drug applications approved by US FDA as of 16-30 June 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.